Based on the filed figures, annual revenue rose from KRW 1.7 trillion in 2022 to KRW 1.81 trillion in 2023 (up 6.9%), KRW 1.94 trillion in 2024 (up 6.8%) and KRW 2.07 trillion in 2025 (up 6.8%), marking three straight years of growth from 2023 through 2025.
Operating profit was KRW 207.3 billion in 2022, KRW 195.6 billion in 2023 (down 5.7%), KRW 281.9 billion in 2024 (up 44.1%) and KRW 261.8 billion in 2025 (down 7.1%). Revenue kept rising while operating profit fell after its 2024 peak, and the operating margin slid from 14.6% in 2024 to 12.7% in 2025.
Net profit attributable to controlling shareholders was KRW 102.6 billion in 2022, KRW 152.7 billion in 2023, KRW 57.9 billion in 2024 (down 62.1%) and KRW 175.1 billion in 2025 (up 202.4%), so earnings recovered in 2025 from the 2024 low.
Net profit including non-controlling interests was KRW 68.9 billion in 2024 and KRW 227.9 billion in 2025, and the gap between that figure and the controlling-shareholder figure in 2025 reflects non-controlling interests.
Quarterly operating profit bottomed at KRW 34.8 billion in Q4 2025, down 56.8% from the prior quarter, and then rose for three consecutive quarters to KRW 47.8 billion in Q1 2026, KRW 76.6 billion in Q2 and KRW 88.8 billion in Q3.
Revenue fell to KRW 492.7 billion in Q1 2026 and then rose to KRW 570.8 billion in Q2 and KRW 594.1 billion in Q3, two straight quarters of growth. In Q3 2026, operating profit grew 10.3% year on year, faster than the 9.6% revenue growth.
Net profit attributable to controlling shareholders peaked at KRW 69.9 billion in Q4 2025 and then fell for three consecutive quarters to KRW 35.3 billion, KRW 34.1 billion and KRW 32 billion in Q3 2026. The sum of the last four quarters of controlling-shareholder net profit is KRW 171.2 billion.
At the end of 2025, equity totaled KRW 1.77 trillion, of which the controlling-shareholder portion was KRW 1.18 trillion, and total liabilities were KRW 1.46 trillion. The debt ratio rose from 64.2% in 2023 to 81.1% in 2024 and 82.9% in 2025.
Operating cash flow was KRW 257.6 billion in 2025, up from KRW 162.4 billion in 2024. Separately, Daewoong Pharma's provisional separate-basis Q3 2026 operating profit was KRW 76.8 billion, up 43.5% year on year (disclosed November 4, 2026), which is a subsidiary figure and not Daewoong's own result.